BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37977655)

  • 21. Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma.
    Gholiha AR; Hollander P; Glimelius I; Hedstrom G; Molin D; Hjalgrim H; Smedby KE; Hashemi J; Amini RM; Enblad G
    Blood Adv; 2021 Mar; 5(6):1671-1681. PubMed ID: 33720338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP.
    Jachimowicz RD; Pieper L; Reinke S; Gontarewicz A; Plütschow A; Haverkamp H; Frauenfeld L; Fend F; Overkamp M; Jochims F; Thorns C; Leo Hansmann M; Möller P; Rosenwald A; Stein H; Reinhardt HC; Borchmann P; von Tresckow B; Engert A; Klapper W
    Haematologica; 2021 Jun; 106(6):1684-1692. PubMed ID: 32381573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.
    Paydas S; Bağır E; Seydaoglu G; Ercolak V; Ergin M
    Ann Hematol; 2015 Sep; 94(9):1545-52. PubMed ID: 26004934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD30 expression utilization for the accuracy of classical Hodgkin's lymphoma staging.
    Flangea C; Potencz E; Mihăescu R; Anghel A; Gîju S; Motoc M; Dogaru C
    Rom J Morphol Embryol; 2006; 47(2):113-7. PubMed ID: 17106517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.
    Takahashi E; Tsuchida T; Baba S; Tsuzuki T; Shimauchi T; Tokura Y; Tamada Y; Nakamura S
    Pathol Int; 2020 Oct; 70(10):804-811. PubMed ID: 32783303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma.
    Diepstra A; van Imhoff GW; Karim-Kos HE; van den Berg A; te Meerman GJ; Niens M; Nolte IM; Bastiaannet E; Schaapveld M; Vellenga E; Poppema S
    J Clin Oncol; 2007 Jul; 25(21):3101-8. PubMed ID: 17536082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases.
    Kubes V; Kren L; Sokol F; Michalka J; Muzik J; Arpas T; Krenova Z; Kral Z
    In Vivo; 2023; 37(4):1735-1742. PubMed ID: 37369476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma.
    Hansen HP; Engels HM; Dams M; Paes Leme AF; Pauletti BA; Simhadri VL; Dürkop H; Reiners KS; Barnert S; Engert A; Schubert R; Quondamatteo F; Hallek M; Pogge von Strandmann E
    J Pathol; 2014 Mar; 232(4):405-14. PubMed ID: 24659185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-L1 Immunohistochemistry Highlights Bone Marrow Involvement by Classic Hodgkin Lymphoma in Staging Biopsies: Implications for Diagnosis and Tumor Microenvironment Alterations.
    Xing W; Mai N; Dresser K; Chen BJ
    Appl Immunohistochem Mol Morphol; 2019; 27(5):356-363. PubMed ID: 29271790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization.
    Hartmann S; Martin-Subero JI; Gesk S; Hüsken J; Giefing M; Nagel I; Riemke J; Chott A; Klapper W; Parrens M; Merlio JP; Küppers R; Bräuninger A; Siebert R; Hansmann ML
    Haematologica; 2008 Sep; 93(9):1318-26. PubMed ID: 18641027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic Utility of STAT6 and pSTAT6 Immunohistochemistry for Distinguishing Classic Hodgkin Lymphoma and Peripheral T-Cell Lymphoma With Hodgkin and Reed-Sternberg-like Cells.
    Satou A; Takahara T; Yamashita D; Seki M; Kato S; Tanioka F; Tsuyuki T; Wada E; Sakurai K; Karube K; Tsuzuki T; Nakamura S
    Am J Surg Pathol; 2023 Aug; 47(8):897-906. PubMed ID: 37248961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
    Zhu J; Wen H; Bi R; Wu Y; Wu X
    J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
    Sakakibara A; Kohno K; Ishikawa E; Suzuki Y; Tsuyuki Y; Shimada S; Shimada K; Satou A; Takahara T; Ohashi A; Takahashi E; Kato S; Nakamura S; Asano N
    J Clin Exp Hematop; 2021 Dec; 61(4):182-191. PubMed ID: 34511582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of programmed death ligand-1 and programmed death-1 expression in patients with upper tract urothelial carcinoma.
    Campedel L; Compérat E; Cancel-Tassin G; Varinot J; Pfister C; Delcourt C; Gobet F; Roumiguié M; Patard PM; Daniel G; Bigot P; Carrouget J; Eymerit C; Larré S; Léon P; Durlach A; Ruffion A; de Mazancourt ES; Decaussin-Petrucci M; Bessède T; Lebacle C; Ferlicot S; Robert G; Vuong NS; Philip M; Crouzet S; Matillon X; Mège-Lechevallier F; Lang H; Mouracade P; Lindner V; Gougis P; Cussenot O; Rouprêt M; Seisen T
    BJU Int; 2023 Nov; 132(5):581-590. PubMed ID: 37488983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
    Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
    Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study.
    Vandenberghe P; Wlodarska I; Tousseyn T; Dehaspe L; Dierickx D; Verheecke M; Uyttebroeck A; Bechter O; Delforge M; Vandecaveye V; Brison N; Verhoef GE; Legius E; Amant F; Vermeesch JR
    Lancet Haematol; 2015 Feb; 2(2):e55-65. PubMed ID: 26687610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.
    Aoki T; Chong LC; Takata K; Milne K; Marshall A; Chavez EA; Miyata-Takata T; Ben-Neriah S; Unrau D; Telenius A; Boyle M; Weng AP; Savage KJ; Scott DW; Farinha P; Shah SP; Nelson BH; Steidl C
    Proc Natl Acad Sci U S A; 2021 Oct; 118(41):. PubMed ID: 34615710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
    Xian F; Ren D; Bie J; Xu G
    Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased STAT expression in Reed-Sternberg cells as a potential positive prognostication biomarker in Hodgkin lymphoma.
    Zargari A; Cummins KD; Hosking P; Pham A; Hawkes E; Ting SB
    Pathology; 2023 Aug; 55(5):650-655. PubMed ID: 37169648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.